(MENAFN) Actavis is holding talks with rival drug maker Forest Laboratories for an acquisition in a deal that is expected to value Forest at USD25 billion, The Peninsula Qatar reported
The deal was expected to be announced recently, but talks could possibly fall apart, the Wall Street Journal said
A combined Actavis-Forest will offer a range of generic and brand-name medicines. Actavis competes with larger drugmakers such as Teva Pharmaceuticals Industries Ltd and Mylan Inc
Market capitalization for Forest is at USD19.34 billion, versus USD33.40 billion for Actavis
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.